Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Be6A Lung-01
jRCT2031240261Phase 3Active, not recruiting
- Sponsor
- Pfizer
- Start
- Jul 2024
- Modality
- Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
01
Overview
Phase 3, randomised, open-label trial in non-small cell lung cancer (NSCLC) comparing Sigvotatug vedotin with Docetaxel (2 arms). Primary endpoints: Overall Survival and Confirmed Objective Response Rate by BICR. Started Jul 2024; status: active, not recruiting.
02
Drugs
sigvotatug vedotindocetaxel
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on jRCT2031240261.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2031240261.